Cells expressing anti-Fc receptor binding components

Details Cells expressing anti-Fc receptor binding components Cells expressing anti-Fc receptor binding components

2008-01-08

2008-01-08

Wehbe, Anne M. (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093210, C435S325000, C435S326000, C435S320100, C435S328000

Reexamination Certificate

active

07316812

ABSTRACT:
Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.

REFERENCES:
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4676980 (1987-06-01), Segal et al.
patent: 4954617 (1990-09-01), Fanger et al.
patent: 5635600 (1997-06-01), Fanger et al.
patent: 6682928 (2004-01-01), Keler et al.
patent: 19634159 (1997-09-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO-91/00360 (1991-01-01), None
patent: WO-91/05871 (1991-05-01), None
patent: WO-91/03493 (1992-03-01), None
patent: WO-92/05793 (1992-04-01), None
patent: WO-92/10591 (1992-06-01), None
patent: WO-92/15322 (1992-09-01), None
patent: WO-94/10332 (1994-05-01), None
patent: WO-95/09917 (1995-04-01), None
patent: WO-96/40789 (1996-12-01), None
patent: WO-97/07218 (1997-02-01), None
patent: WO-97/20048 (1997-06-01), None
patent: WO 97/20048 (1997-06-01), None
patent: WO-97/35004 (1997-09-01), None
Miller et al. (1995) FASEB, vol. 9, 190-1999.
Deonarain et al. (1998) Exp. Opin. Ther. Patents, vol. 8 (1) 53-69.
Guyre et al. (1997) Can. Immunol. Immunother., vol. 45, 146-148.
Guyre et al. (1997) Canc. Immunol. Immunother., vol. 45, 146-148, 1997.
Daeron et al. (1997) Annu. Rev. Immunol., vol. 15, 203-234, 1997.
Miller et al. (1995) FASEB, vol. 9, 190-199, 1995.
Deonarain et al. (1998) Exp. Opin. Ther. Patents, vol. 8 (1), 53-69, 1998.
Anderson, C. et al. (1986) “Stimulation of Superoxide Production by a Monoclonal Antibody (mab) Against the High affinity IgG Fc Receptor (FcRI) of U937 Cells”, Fed. Proc., 45: 714, Abstract #3247.
Ball, E. et al. (1992) “Initial Trial of Bispecific Antibody-Mediated Immunotherapy of CD15-Bearing Tumors: Cytotoxicity of Human Tumor Cells Using a Bispecific Antibody Comprised of Anti-CD15 (MoAb PM81) and Anti-CD64/Fc.gamma.RI (MoAb32)”, J. of Hematotherapy, 1:85-94.
Brennan, M. et al. (1985) “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G.sub.1 Fragments”, Science, 229: 81-83.
Chang, T. W. (1985) “Regulation of immune response by antibodies: the importance of antibody and monocyte Fc receptor interaction in T cell activation”, Immun. Today, 6:245.
Chen, J. et al. (1985) “An Immunoconjugate of Lys3-Bombesin and Monoclonal Antibody 22 Can Specifically Induce FcgammaRI (CD64)-Dependent Monocyte- and Neutrophil-Mediated Lysis of Small Cell Carcinoma of the Lung Cells”, Clinical Cancer Research, 1 (4):425-434.
Clark, M. et al. (1990) “Use of Bispecific Monoclonal Antibodies to Treat Hematological Malignancies: A Model System Using CD3 Transgenic Mice”, Bispecific Antibodies and Targeted Cellular Cytotoxicity, Edited by Romet-Lemonne et al., Fondation Nationale de Transfustion Sanguine, Les Ulis, France, pp. 243-247.
de Leij, L. et al. (1990) “Intrapleural and Intraperitoneal Application of Bispecific Antibody Retargeted Lymphocytes to Cancer Patients”, Bispecific Antibodies and Targeted Cellular Cytotoxicity, Edited by Romet-Lemmone et al., Fondation Nationale de Transfusion Sanguine, Les Ulis, France, pp. 249-253.
de Palazzo, I. et al. (1990) “Potentiation of Tumor Lysis by a Bispecific Antibody that Binds to CA19-9 Antigen and the Fc.gamma. Receptor Expressed by Human Large Granular Lymphocytes”, Cancer Research, 50:7123-7128.
Dillman, R. (1989) “Monoclonal Antibodies for Treating Cancer”, Annals of Interal Medicine, 111:592-603.
Ericson, S. et al. (1994) “The Effect of Recombinant Human Interleukin-3 and Recombinant Human Granulocyte-macro-Phage Colony-Stimulating Factor on Fc.gamma. Receptor Expression and Antibody-Dependent Cellular Cytotoxicity of Hematopoietic Progenitor Cells During in Vitro Myeloid Maturation”, Experimental Hematology, 22:283-289.
Falo et al. (1995) “Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity”, Nat. Med. 1:649.
Fanger, M. et al. (1994) “Production and Use of Anti-FcR Bispecific Antibodies” Immunomethods 4 (1): 72-81.
Fanger, M. et al. (1992) “Fc.gamma. Receptors in Cancer and Infectious Disease”, Immunol. Res., 11:203-216.
Fanger, M. et al. (1992) “Bispecific Antibodies” Critical Reviews in Immunology, 12 (3,4):101-124.
Gosselin et al. (1992) “Enhanced antigen presentation using human Fcg receptor (monocyte/macrophage)-specific immunogens”, J. Immun. 149:3477.
Graziano, R. et al. (1995) “Construction and Characterization of a Humanized Anti-Gamma-Ig Receptor Type I (Fcgamma RI) Monoclonal Antibody” The Journal of Immunology, 155 (10): 4996-5002.
Guyre, P. et al. (1989) “Monoclonal Antibodies that Bind to Distinct Epitopes on Fc.gamma.RI are able to Trigger Receptor Function”, The Journal of Immunology, 143 (5), pp. 1650-1655.
Guyre, P. et al. (1983) “Recombinant Immune Interferon Increases Immunoglobulin G Fc Receptors on Cultured Human Mononuclear Phagocytes”, Journal of Clinical Investigation, 72:393-397.
Harris, W. et al. (1993) “Therapeutic Antibodies—The Coming of Age”, Tibtech, 11:42-44.
Hird, V. et al. (1990) “Immunotherapy with Monoclonal Antibodies”, Genes and Cancer, Edited by D. Carney and K. Sikora, Chapter 17, pp. 183-189.
Isturiz, M. et al. (1991) “Two Different Fc.gamma. Receptor-Dependent Cytotoxic Mechanisms Triggered by Monoclonal Immunoglobulins”, Immunology Letters, 29:271-276.
Jung, Gundram, et al., 1991, “Target Cell-Induced T cell Activation with Bi- and Trispecific Antibody Fragments”, Eur. J. Immunol., 21:2431-2435.
Karpovsky, B. et al. (1984) “Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc.gamma. Receptor Antibodies”, Journal of Experimental Medicine, 160:1686-1701.
Kovacsovics-Bankowski et al. (1993) “Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages”, Proc. Natl. Acad. Sci. USA, 90:4942.
Liu, M. et al. (1985) “Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes”, PNAS, 82:8648-8652.
Looney, R. et al. (1986) “Human Monocytes and U937 Cells Bear Two Distinct Fc Receptors for IgG”, The Journal of Immunology, 136 (5):1641-1647.
Lubeck, M. et al. (1985) “The Interaction of Murine IgG Subclass Proteins with Human Monocyte Fc Receptors”, The Journal of Immunology, 135 (2):1299-1304.
Mabondzo, A. et al. (1994) “Antibody-dependent Cellular Cytotoxicity and Neutralization of Human Immunodeficiency Virus Type 1 by High Affinity Corss-Linking of gp41 to Human Macrophage Fc IgG Receptor Using Bispecific Antibody”, Journal of Virology, 75:1451-1456.
Nitta, T. et al. (1990) “Preliminary Trial of Specific Targeting Therapy Against Malignant Glioma”, The Lancet, 335:368-376.
Perez, P. et al. (1985) “Specific Targeting of Cytotoxic T Cells by Anti-Target Cell Antibody”, Nature, 316:354-356.
Repp, R. et al. (1994) “G-CSF Stimulated Neutrophils As Effector Cells In Immunotherapy With A Bispecific Antibody to FcgammaRI and To HER-2
eu (MDX210): Preclinical Studies”, Immunobiology, 191 (2-3): 250-251.
Sarmay, G. et al. (1992) “Mapping and Comparison of the Interaction Sites on The Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fc.gamma. Receptor”, Molecular Immunology, 29 (5):633-639.
Schlom, J. (1991) “Monoclonal Antibodies: They're More and Less Than You Think”, Molecular Foundations of Biology Edited by Williams and Wilkins, Chapter 6, pp. 95-134.
Shen, L. et al. (1984) “Direct Stimu

Affiliated with

Also associated with

Rating

Cells expressing anti-Fc receptor binding components does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cells expressing anti-Fc receptor binding components, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cells expressing anti-Fc receptor binding components will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2815056